| Name | Aztreonam |
| Description | Aztreonam (SQ-26,776), a monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum, possesses bactericidal activity. |
| In vitro | Aztreonam causes significant suppression of human colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. [1] Aztreonam is hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange. Aztreonam is extremely stable as to the typical class C cephalosporinase of Citrobacter freundii, and acts as a competitive and progressive inhibitor for the beta-lactamase. [2] Aztreonam (AZT) combined with clindamycin (CLDM) has synergistic effects on Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Haemophilus influenzae, which are sensitive or quasi-sensitive to CLDM, in the presence of CLDM at MIC or sub-MIC. [3] Aztreonam reduces the cfu of some strains by 1 log unit without preserving the integrity of cystic fibrosis airway cell monolayers, while decreasing the biofilms of other clinical isolates by 4 log units and protecting the monolayers from being compromised. [4] |
| In vivo | Aztreonam (300 mg/kg) results in a significant decrease in the content of hepatic microsomal P450, while no significant change is observed in hepatic cytochrome b5 content and NADPH-cytochrome c (P450) reductase activity. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 9 mg/mL (20.67 mM), Sonication is recommended.
DMSO : 50 mg/mL (114.83 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | β-Lactamase | PBPs | Inhibitor | inhibit | Bacterial | Aztreonam | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | Urethane | Sulfamethoxazole sodium | Doxycycline | EDTA copper(II) disodium salt | Isoeugenol | Dimethyl sulfoxide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pediatric Drug Library | ReFRAME Related Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Microbial Natural Product Library | NO PAINS Compound Library | Anti-Fibrosis Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max |
United States
